New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2014
11:51 EDTSLXPSalix could be next M&A target, says Buckingham
Buckingham said Salix could be the next take-over target, especially for an Irish domiciled acquirer that can leverage its efficient tax structure, following recent M&A in the space. The firm said Salix offers a potential suitor a branded product pipeline of high growth drugs. Shares are Buy rated with a $125 price target.
News For SLXP From The Last 14 Days
Check below for free stories on SLXP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent SLXP news | >>
August 19, 2014
13:28 EDTSLXPJazz moves higher after WSJ report of Salix approach by Allergan
Subscribe for More Information
13:15 EDTSLXPSalix options active after WSJ report of Allergan approach
Subscribe for More Information
13:13 EDTSLXPAllergan approached Salix, one other about takeover, WSJ reports
Subscribe for More Information
13:06 EDTSLXPSalix jumps 6% to $147.85 after WSJ report of Allergan approach
Subscribe for More Information
13:05 EDTSLXPAllergan approached Salix about takeover, WSJ reports
07:02 EDTSLXPSalix announces early termination of HSR Waiting Period for Cosmo transaction
Subscribe for More Information
August 18, 2014
17:18 EDTSLXPVisium Asset Management reports 4.9 % passive stake in Salix
Subscribe for More Information
11:41 EDTSLXPCubist rises after report sparks takeover interest speculation
Subscribe for More Information
August 14, 2014
14:17 EDTSLXPViking Global Investors reports 5.0% passive stake in Salix
Subscribe for More Information
August 11, 2014
14:05 EDTSLXPSalix announces results from TARGET 3 trial
Subscribe for More Information
07:06 EDTSLXPSalix, Progenics receive FDA PDUFA date of September 29 for Relistor sNDA
Salix Pharmaceuticals (SLXP) and Progenics Pharmaceuticals (PGNX) announced that the FDA has informed Salix that the supplemental New Drug Application for RELISTOR Subcutaneous Injection, 20 mg/ml, for the treatment of opioid-induced constipation in patients taking opioids for chronic non-cancer pain has been assigned a user fee goal date of September 29.
August 8, 2014
11:16 EDTSLXPSalix post-earnings pullback unwarranted, says Sterne Agee
Subscribe for More Information
August 7, 2014
18:41 EDTSLXPOn The Fly: After Hours Movers
Subscribe for More Information
16:16 EDTSLXPSalix sees FY14 EPS $3.16, consensus $6.53
Sees FY14 revenue approximately $1.6B, consensus $1.63B.
16:15 EDTSLXPSalix sees Q3 EPS $1.53, consensus $1.78
Subscribe for More Information
16:14 EDTSLXPSalix reports Q2 EPS $1.59, consensus $1.72
Subscribe for More Information
15:33 EDTSLXP Notable companies reporting after market close
Subscribe for More Information
15:31 EDTSLXPNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include CBS (CBS), consensus 72c; Consolidated Edison (ED), consensus 54c; Monster Beverage (MNST), consensus 75c; News Corporation (NWSA), consensus 3c; NVIDIA (NVDA), consensus 20c; Computer Sciences (CSC), consensus 94c; CareFusion (CFN), consensus 72c;DeVry Education (DV), consensus 67c; Salix Pharmaceuticals (SLXP), consensus $1.72; Federal Realty (FRT), consensus $1.21; SolarCity (SCTY), consensus (99c); Medivation (MDVN), consensus 24c; Sprouts Farmers Market (SFM), consensus 18c; Alnylam Pharmaceuticals (ALNY), consensus (56c); Lions Gate (LGF), consensus 17c; Mercadolibre (MELI), consensus 56c; Post Holdings (POST), consensus 27c; Assured Guaranty (AGO), consensus 35c; Great Plains Energy (GXP), consensus 41c; Air Lease (AL), consensus 52c; Ubiquiti Networks (UBNT), consensus 51c; SemGroup (SEMG), consensus 35c.
August 6, 2014
10:00 EDTSLXPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:33 EDTSLXPSalix upgraded to Buy from Hold at Cantor
Subscribe for More Information
1 | 2 | all recent SLXP news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use